Arq. Bras. Cardiol. 2025; 122(6): e20250312
Alcohol Septal Ablation in Brazil: Insights from the BRASA Registry
Maria Antonieta Albanez A. de Medeiros Lopes
, Mayara Viana, Júlia Nóbrega
, Heitor N. Albanez A. de Medeiros, Gláucia Maria Moraes de Oliveira
This Short Editorial is referred by the Research article "Brazilian Multicenter Registry of Alcohol Septal Ablation for Patients with Symptomatic Hypertrophic Obstructive Cardiomyopathy – BRASA Registry".
The Brazilian Multicenter Registry of Alcohol Septal Ablation (BRASA Registry), published in ABC Cardiol in 2025, represents a pivotal contribution to understanding the safety, efficacy, and real-world applicability of Alcohol Septal Ablation (ASA) in Brazil—a country marked by healthcare disparities and a high burden of cardiovascular diseases. This registry provides unprecedented data on ASA outcomes in Brazilian centers, reinforcing its role as a viable alternative to surgical myectomy in hypertrophic obstructive cardiomyopathy (HOCM).
Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disorder, historically associated with high morbidity and mortality. However, advances in diagnostic imaging, pharmacological therapies, and interventional techniques have transformed HCM into a treatable condition, with many patients now achieving near-normal life expectancy. Over the past two decades, mortality rates have declined dramatically—from 6% to 0.5% per year—largely due to early risk stratification, implantable cardioverter-defibrillators, and septal reduction therapies.
[…]
77